Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

The popularity of weight loss drugs has caused a shortage in recent years, but how effective are they at helping with food ...

A Brazilian influencer revealed her former boyfriend applied a weight loss medication to her body while she slept because he ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...